阿托伐他汀强化治疗对非ST段抬高急性心肌梗死患者的抗炎、抗心肌缺血作用  

Anti-inflammatory and anti-myocardial ischemic effects of atorvastatin intensive treatment towards non-ST elevation acute myocardial infraction patients

作　　者：季清[1] 陈阳[1] 孙彩琴[1] 

机构地区：[1]靖江市人民医院心血管内科,江苏靖江214500

出　　处：《江苏大学学报（医学版）》2008年第2期146-149,共4页Journal of Jiangsu University：Medicine Edition

摘　　要：目的：探讨阿托伐他汀强化治疗对非ST段抬高急性心肌梗死（NSTEMI）患者的抗炎、抗心肌缺血作用。方法：选择93例NSTEMI患者，随机分为两组，治疗组47例，给予阿托伐他汀钙30～40mg／d口服；对照组46例，给予阿托伐他汀钙10mg／d口服，疗程均为9个月。观察两组患者治疗前、后的临床疗效、心电图（EKG）心肌缺血、C反应蛋白（CRP）及血脂改变情况。结果：两组患者治疗前后低密度脂蛋白胆固醇（LDL-C）、三酰甘油（TG）、总胆固醇（TC）明显下降，差异有统计学意义（P〈0．01）；治疗组治疗后CRP，LDL-C，TG，TC较对照组下降明显（P〈0．01），临床症状改善组间差异有统计学意义（P〈0．01），EKG示心肌缺血明显改善、缺血事件明显减少，差异亦有统计学意义（P〈0．01）。结论：阿托伐他汀强化治疗效果良好，具有抗炎、抗心肌缺血作用。他汀类药物强化治疗对防治NSTEMI有重要意义。Objective： To explore the anti-inflammatory and anti-myocardial ischemic effects of Atorvastatin intensive treatment towards non-ST elevation acute myocardial infraction （NSTEMI）. Methods： All 93 NSTEMI patients choosing in random were divided into two groups. Intensive treatment group （47 cases ） chose Atorvastatin made in Huirui Company. It was taken orally 30～40 mg/d. The common treatment group （46 cases） was taken orally 10 mg/d. The course of treatment was nine months. Results： Compared with the past the LDL-C,TG,TC in these two groups fell obviously（P 〈 0. 01 ）. Compared with the past the LDL- C, TG, TC, C-reactive protein （CRP） in the intensive treatment group fell obviously （P 〈 0.01 ）. The abnormity in clinical symptom alleviatition and EKG recording ischem.ic alleviated was also significant （P 〈 0.01 ）. EKG recorded ischemic related events was lower than that in common group（P 〈0.01 ）. Conclusion： Atorvastatin intensive treatment had the anti-inflammatory and anti-myocardial ischemic effect. It had important meaning in the prevention and cure of NSTEMI with tatin drugs.

关 键 词：阿托伐他汀 强化治疗 非ST段抬高急性心肌梗死 

分 类 号：R972.3[医药卫生—药品]